<?xml version='1.0' encoding='utf-8'?>
<document id="30949521"><sentence text="Risk and Cost Associated With Drug-Drug Interactions Among Aging HIV Patients Receiving Combined Antiretroviral Therapy in France." /><sentence text="We aimed to describe the frequency, risk factors, and costs attributable to drug-drug interactions (DDIs) among an aging French HIV population" /><sentence text="" /><sentence text="We conducted a retrospective cohort study using French nationwide health care e-records: the SNIIRAM database" /><sentence text=" People living with HIV (PLWH) aged &gt;65 years and receiving combined antiretroviral treatment (cART) during 2016 were included" /><sentence text=" A DDI was defined as &quot;These drugs should not be co-administered,&quot; represented by a red symbol on the University of Liverpool website" /><sentence text=" Attributable DDIs' cost was defined as the difference between individuals with and without DDIs regarding all reimbursed health care acts" /><sentence text="" /><sentence text="Overall, 9076 PLWH met the study criteria" /><sentence text=" Their baseline characteristics were: mean age, 71" /><sentence text="3 Â± 4" /><sentence text="9 years; 25% female; median HIV duration (interquartile range [IQR]), 16" /><sentence text="2 (9" /><sentence text="5-20" /><sentence text="3) years; median comorbidities (IQR), 2 (1-3)" /><sentence text=" During 2016, they received a median (IQR) of 14 (9-21) comedications (non-cART), and 1529 individuals had at least 1 DDI (16" /><sentence text="8%; 95% confidence interval [CI], 16" /><sentence text="1-17" /><sentence text="6)" /><sentence text=" In multivariate analysis, raltegravir or dolutegravir plus 2 nucleoside reverse-transcriptase inhibitors (NRTIs) significantly and independently reduced the risk of DDIs (adjusted odds ratio [aOR], 0"><entity charOffset="27-38" id="DDI-PubMed.30949521.s20.e0" text="raltegravir" /><entity charOffset="42-54" id="DDI-PubMed.30949521.s20.e1" text="dolutegravir" /><pair ddi="false" e1="DDI-PubMed.30949521.s20.e0" e2="DDI-PubMed.30949521.s20.e0" /><pair ddi="false" e1="DDI-PubMed.30949521.s20.e0" e2="DDI-PubMed.30949521.s20.e1" /></sentence><sentence text="02; 95% CI, 0"><entity charOffset="8-10" id="DDI-PubMed.30949521.s21.e0" text="CI" /></sentence><sentence text="005-0" /><sentence text="050; P &lt; " /><sentence text="0001) compared with non-nucleoside reverse-transcriptase inhibitor plus 2 NRTIs, whereas cART with boosted agents (protease inhibitors or elvitegravir) significantly increased the risk (aOR, 4" /><sentence text="12; 95% CI, 3"><entity charOffset="8-9" id="DDI-PubMed.30949521.s25.e0" text="CI" /></sentence><sentence text="34-5" /><sentence text="10; P &lt; " /><sentence text="0001)" /><sentence text=" Compared with propensity score-matched PLWH without DDIs, the presence of DDIs was associated with a $2693 additional cost per year (P &lt; " /><sentence text="0001)" /><sentence text="" /><sentence text="The presence of DDIs is frequent and significantly increases health care costs in the aging population of PLWH" /><sentence text="" /></document>